He may be remembered as the best thing George Bush did (or as the one good thing he did, depending on where you stand). Elias Zerhouni announced yesterday that he would step down from his position as NIH director at the end of October. Look at this blog post from Peter Suber to find out more about how Zerhouni helped the advance the open access movement during his tenure.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.